BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nik ME, Momtazi‐borojeni AA, Zamani P, Navashenaq JG, Iranshahi M, Jaafari MR, Malaekeh‐nikouei B. Targeted‐nanoliposomal combretastatin A4 (CA‐4) as an efficient antivascular candidate in the metastatic cancer treatment. J Cell Physiol 2019;234:14721-33. [DOI: 10.1002/jcp.28230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Mirzavi F, Barati M, Vakili-Ghartavol R, Roshan MK, Mashreghi M, Soukhtanloo M, Jaafari MR. Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model. Int J Pharm 2021;613:121396. [PMID: 34942328 DOI: 10.1016/j.ijpharm.2021.121396] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Shabgah AG, Suksatan W, Achmad MH, Bokov DO, Abdelbasset WK, Ezzatifar F, Hemmati S, Mohammadi H, Soleimani D, Jadidi-Niaragh F, Ahmadi M, Navashenaq JG. Arctigenin, an anti-tumor agent; a cutting-edge topic and up-to-the-minute approach in cancer treatment. Eur J Pharmacol 2021;909:174419. [PMID: 34391770 DOI: 10.1016/j.ejphar.2021.174419] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Nik ME, Jaafari MR, Mashreghi M, Nikoofal-Sahlabadi S, Amin M, Sadeghnia HR, Iranshahi M, Navashenaq JG, Malaekeh-Nikouei B. The effect of RGD-targeted and non-targeted liposomal Galbanic acid on the therapeutic efficacy of pegylated liposomal doxorubicin: From liposomal preparation to in-vivo studies. Int J Pharm 2021;604:120710. [PMID: 34019972 DOI: 10.1016/j.ijpharm.2021.120710] [Reference Citation Analysis]
4 Gowhari Shabgah A, Hejri Zarifi S, Mazloumi Kiapey SS, Ezzatifar F, Pahlavani N, Soleimani D, Mohammadian Haftcheshmeh S, Mohammadi H, Gholizadeh Navashenaq J. Curcumin and cancer; are long non-coding RNAs missing link? Prog Biophys Mol Biol 2021;164:63-71. [PMID: 33894206 DOI: 10.1016/j.pbiomolbio.2021.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gowhari Shabgah A, Ezzatifar F, Aravindhan S, Olegovna Zekiy A, Ahmadi M, Gheibihayat SM, Gholizadeh Navashenaq J. Shedding more light on the role of Midkine in hepatocellular carcinoma: New perspectives on diagnosis and therapy. IUBMB Life 2021;73:659-69. [PMID: 33625758 DOI: 10.1002/iub.2458] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Kowalczyk P, Trzepizur D, Szymczak M, Skiba G, Kramkowski K, Ostaszewski R. 1,2-Diarylethanols-A New Class of Compounds That Are Toxic to E. coli K12, R2-R4 Strains. Materials (Basel) 2021;14:1025. [PMID: 33671509 DOI: 10.3390/ma14041025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
7 Smolarczyk R, Czapla J, Jarosz-Biej M, Czerwinski K, Cichoń T. Vascular disrupting agents in cancer therapy. Eur J Pharmacol 2021;891:173692. [PMID: 33130277 DOI: 10.1016/j.ejphar.2020.173692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
8 Kargozar S, Baino F, Hamzehlou S, Hamblin MR, Mozafari M. Nanotechnology for angiogenesis: opportunities and challenges. Chem Soc Rev 2020;49:5008-57. [PMID: 32538379 DOI: 10.1039/c8cs01021h] [Cited by in Crossref: 28] [Cited by in F6Publishing: 52] [Article Influence: 14.0] [Reference Citation Analysis]
9 Wei Q, Shen N, Yu H, Wang Y, Tang Z, Chen X. FXIIIa substrate peptide decorated BLZ945 nanoparticles for specifically remodeling tumor immunity. Biomater Sci 2020;8:5666-76. [DOI: 10.1039/d0bm00713g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]